Cargando…
SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity
Sodium/glucose cotransporter 1 (SGLT1), an essential active glucose transport protein that helps maintain high intracellular glucose levels, was previously shown to interact with epidermal growth factor receptor (EGFR); the SGLT1–EGFR interaction maintains intracellular glucose levels to promote sur...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717760/ https://www.ncbi.nlm.nih.gov/pubmed/31199048 http://dx.doi.org/10.1002/1878-0261.12530 |
_version_ | 1783447607619616768 |
---|---|
author | Liu, Huiquan Ertay, Ayse Peng, Ping Li, Juanjuan Liu, Dian Xiong, Hua Zou, Yanmei Qiu, Hong Hancock, David Yuan, Xianglin Huang, Wei‐Chien Ewing, Rob M. Downward, Julian Wang, Yihua |
author_facet | Liu, Huiquan Ertay, Ayse Peng, Ping Li, Juanjuan Liu, Dian Xiong, Hua Zou, Yanmei Qiu, Hong Hancock, David Yuan, Xianglin Huang, Wei‐Chien Ewing, Rob M. Downward, Julian Wang, Yihua |
author_sort | Liu, Huiquan |
collection | PubMed |
description | Sodium/glucose cotransporter 1 (SGLT1), an essential active glucose transport protein that helps maintain high intracellular glucose levels, was previously shown to interact with epidermal growth factor receptor (EGFR); the SGLT1–EGFR interaction maintains intracellular glucose levels to promote survival of cancer cells. Here, we explore the role of SGLT1 in triple‐negative breast cancer (TNBC), which is the most aggressive type of breast cancer. We performed TCGA analysis coupled to in vitro experiments in TNBC cell lines as well as in vivo xenografts established in the mammary fat pad of female nude mice. Tissue microarrays of TNBC patients with information of clinical–pathological parameters were also used to investigate the expression and function of SGLT1 in TNBC. We show that high levels of SGLT1 are associated with greater tumour size in TNBC. Knockdown of SGLT1 compromises cell growth in vitro and in vivo. We further demonstrate that SGLT1 depletion results in decreased levels of phospho‐EGFR, and as a result, the activity of downstream signalling pathways (such as AKT and ERK) is inhibited. Hence, targeting SGLT1 itself or the EGFR–SGLT1 interaction may provide novel therapeutics against TNBC. |
format | Online Article Text |
id | pubmed-6717760 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67177602019-09-04 SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity Liu, Huiquan Ertay, Ayse Peng, Ping Li, Juanjuan Liu, Dian Xiong, Hua Zou, Yanmei Qiu, Hong Hancock, David Yuan, Xianglin Huang, Wei‐Chien Ewing, Rob M. Downward, Julian Wang, Yihua Mol Oncol Research Articles Sodium/glucose cotransporter 1 (SGLT1), an essential active glucose transport protein that helps maintain high intracellular glucose levels, was previously shown to interact with epidermal growth factor receptor (EGFR); the SGLT1–EGFR interaction maintains intracellular glucose levels to promote survival of cancer cells. Here, we explore the role of SGLT1 in triple‐negative breast cancer (TNBC), which is the most aggressive type of breast cancer. We performed TCGA analysis coupled to in vitro experiments in TNBC cell lines as well as in vivo xenografts established in the mammary fat pad of female nude mice. Tissue microarrays of TNBC patients with information of clinical–pathological parameters were also used to investigate the expression and function of SGLT1 in TNBC. We show that high levels of SGLT1 are associated with greater tumour size in TNBC. Knockdown of SGLT1 compromises cell growth in vitro and in vivo. We further demonstrate that SGLT1 depletion results in decreased levels of phospho‐EGFR, and as a result, the activity of downstream signalling pathways (such as AKT and ERK) is inhibited. Hence, targeting SGLT1 itself or the EGFR–SGLT1 interaction may provide novel therapeutics against TNBC. John Wiley and Sons Inc. 2019-06-14 2019-09 /pmc/articles/PMC6717760/ /pubmed/31199048 http://dx.doi.org/10.1002/1878-0261.12530 Text en © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Liu, Huiquan Ertay, Ayse Peng, Ping Li, Juanjuan Liu, Dian Xiong, Hua Zou, Yanmei Qiu, Hong Hancock, David Yuan, Xianglin Huang, Wei‐Chien Ewing, Rob M. Downward, Julian Wang, Yihua SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity |
title | SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity |
title_full | SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity |
title_fullStr | SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity |
title_full_unstemmed | SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity |
title_short | SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity |
title_sort | sglt1 is required for the survival of triple‐negative breast cancer cells via potentiation of egfr activity |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717760/ https://www.ncbi.nlm.nih.gov/pubmed/31199048 http://dx.doi.org/10.1002/1878-0261.12530 |
work_keys_str_mv | AT liuhuiquan sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT ertayayse sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT pengping sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT lijuanjuan sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT liudian sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT xionghua sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT zouyanmei sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT qiuhong sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT hancockdavid sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT yuanxianglin sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT huangweichien sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT ewingrobm sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT downwardjulian sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity AT wangyihua sglt1isrequiredforthesurvivaloftriplenegativebreastcancercellsviapotentiationofegfractivity |